简介: 货 号:A-8644 名 称:Afatinib 别 名:Afatinib Free Base C A S :850140-72-6 分子量:485.94 分子式:C24H25ClFN5O3 纯 度:HPLC/TLC:>99% 说 明:Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO at 200 mg/mL; soluble in ethanol at 25 mg/mL; very poorly soluble in water; maximum solubility in plain water is estimated to be about 50-100 µM; buffers, serum, or other additives may increase or decrease the aqueous solubility. Disposal: A. 文 献:Afatinib inhibits EGFR1 tyrosine kinase (IC50 = 0.5 nM) and EGFR2 (HER2) tyrosine kinase (IC50 = 14 nM). It also suppresses EGF-induced EGFR phosphorylation and cellular proliferation in various cell lines, including EGFR-overexpressing and HER2-expressing cell lines A431, NIH-3T3-HER2, NCI-N87 and BT-474. Oral afatinib induced tumor regression in mice carrying A431 or MDA-MB-453 xenografts. Both xenografts are EGFR-overexpressing and HER2-expressing. Afatinib also showed inhibitory effects in NCI-N87 gastric and SKOV-3 ovarian models. Eskens, F.A., et al. "A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours." Br. J. Cancer 98: 80-85 (2008).Afatinib inhibits the kinase activity of wild-type and activated EGFR and HER2 mutants, including erlotinib-resistant isoforms. Afatinib suppressed proliferation of cancer cell lines and caused tumor regression in xenograft and transgenic lung cancer models, with activity superior to that of erlotinib. Li, D., et al. "BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models." Oncogene 27: 4702-4711 (2008).Combination treatment of HER2(YVMA) transgenic mice or H1781 xenografts with afatinib and rapamycin caused significant tumor shrinkage and was an effective treatment paradigm in the adenosquamous lung tumor model in mice. Perera, S.A., et al. "HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy." Proc. Natl. Acad. Sci. USA 106: 474-479 (2009).The EGFR T854A mutation reduces the inhibition of tyrosine phosphorylation by erlotinib. Afatinib overcomes the resistance. Bean, J., et al. "Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma." Clin. Cancer Res. 14: 7519-7525 (2008).Tumors overexpressing EGFR with the secondary T790M point mutation show resistance to the first-generation EGFR inhibitors gefitinib and erlotinib. Such resistance is overcome by afatinib. Minkovsky, N. and Berezov, A. "BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors." Curr. Opin. Investig. 9: 1336-1346 (2008).